Innovative Irinotecan-Loaded Nanomicelles Will Enter Phase I Clinical Trial in 2021

Recent progress at the National Center for Nanoscience and Technology of China has enabled an extremely facile method to encapsulate irinotecan (CPT-11) into micelle-based nanoparticles (named as IH-NM). In preclinical study, compared with free CPT-11, IH-NM exhibited 1.56-fold higher maximum tolera...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Chan, Xu, Jing, Gan, Yaling, Liang, Xing-Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Translational Patent
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454605/
https://www.ncbi.nlm.nih.gov/pubmed/34557721
http://dx.doi.org/10.1016/j.xinn.2020.100057
Descripción
Sumario:Recent progress at the National Center for Nanoscience and Technology of China has enabled an extremely facile method to encapsulate irinotecan (CPT-11) into micelle-based nanoparticles (named as IH-NM). In preclinical study, compared with free CPT-11, IH-NM exhibited 1.56-fold higher maximum tolerance dose (MTD), ∼2.45-fold higher antitumor efficacy at 80% of MTD dosage, higher plasma exposure, and slower clearance from the plasma. The IH-NM technology received Clinical Trial Permission from the National Medical Products Administration (NMPA) of China on Mar 6, 2019. The Phase I clinical trial is under preparation.

Ejemplares similares